INTRODUCTION AND OBJECTIVES: Recent analysis identified luminal and basal gene expression subtypes of human bladder cancer (BLCa) with prognostic significance. We reported that loss of the luminal transcription factor FOXA1 is associated with poor clinical outcome and that FOXA1 cooperates with GATA3 and PPARg to reprogram human basal BLCa cells into cells expressing a luminal gene expression pattern. Interestingly, RNA-seq analysis showed that expression of the transcription factors TFAP2A and TFAP2C, which are involved in squamous differentiation (SqD), are repressed following PPARg activation. Therefore, in this study we investigated the role of TFAP2A and TFAP2C in basal human bladder cancers.
METHODS: Computational data analysis using TCGA data was used to determine if TFAP2A and TFAP2C expression is correlated with gene expression subtype. Immunohistochemistry (IHC) of clinical bladder cancer samples was performed to determine the correlation of TFAP2A and TFAP2C expression with SqD and clinical attributes of aggressive disease. Western blotting was also performed to investigate the expression of TFAP2A and TFAP2C in human BLCa cell lines. Finally, we performed tissue recombination xenografting using TFAP2C-overexpressing BLCa cells to assess in vivo tumorigenicity.
RESULTS: Computational analysis showed increased expression of TFAP2A and TFAP2C is significantly associated with a basal gene expression subtype in BLCa. In addition, IHC of human BLCa tissue revealed TFAP2A expression is significantly associated with SqD and lymph node metastasis, while TFAP2C expression was significantly associated with SqD and distant recurrence. Western blotting of 10 human BLCa cell lines showed that TFAP2A and TFAP2C are highly expressed in cells identified by us as robust models of basal disease. Activation of the luminal master regulator PPARg by rosiglitazone induced a reduction in TFAP2A expression in SW780, UMUC1, and 5637 cell lines. Moreover, reduction in TFAP2A expression following rosiglitazone treatment was prevented by treatment with a PPARg antagonist. Finally, tissue recombination xenografting using T24 and UMUC3 cells stably overexpressing TFAP2C enhanced tumor formation in vivo.
CONCLUSIONS: TFAP2A and TFAP2C are novel molecular markers of basal BLCa and SqD. Expression of these transcription factors is an indicator of poor clinical outcome. In addition, TFAP2A is a PPARg repressed gene and overexpression of TFAP2C increases in vivo tumorigenicity. invasive urinary bladder cancer (UBC). There is currently no gold standard for salvage intravesical therapy after BCG treatment failure. To develop the substitute for BCG treatment failure, we focused on gdT cell immunotherapy. gdT cells exert potent cytotoxicity towards various cancer cells and can recognize isopentenyl pyrophosphate (IPP) through the TCRgd receptor, and zoredronic acid (ZOL) pretreatment is widely used to induce IPP accumulation in cancer cells. In this study, we hilighted two issues; combined use of anticancer agents along with ZOL and a bladder instillation approach. The aims are to improve recognition of cancer cells by gdT cells and to increase E/T (Effector/Target) ratio.
METHODS: We examined the efficacy of ex vivo-expanded gdT cell immunotherapy. Flow cytometric analysis of CFSE/propidium iodide (PI) staining was used in in vitro cytotoxicity assays.After co-culture for 4 h, CFSE/PI double positive population was measured as apoptotic cancer cells. In in vivo experiment, the efficacy of ex vivo-expanded gdT cell immunotherapy was examined in an orthotopic xenograft model using In Vivo Imaging System (IVIS).
RESULTS: Ex vivo-expanded gdT cells showed potent cytotoxicity against UBC cells in in vitro assays. Combination treatment with standard anticancer agents showed that low dose gemcitabine pretreatment significantly enhanced the cytotoxicity of gdT cells by upregulating the expression of MICA and MICB (MICA/B), which are tumorassociated antigens recognized by gdT cells. These effects were abrogated by small interfering RNA-mediated knockdown of MICA/B in UBC cells. IVIS analysis revealed the potent cytotoxicity of weekly intravesical administration of gdT cells ( Figure. 1), and weekly gemcitabine pretreatment enhanced the cytotoxicity of gdT cells in vivo.
CONCLUSIONS: Low dose gemcitabine pretreatment significantly enhanced the cytotoxicity of gdT cells by upregulating the expression MICA/B in in vitro. Intravesical gdT cell immunotherapy exerted potent cytotoxicity against UBC and intravesical gdT cell immunotherapy in combination with low dose gemcitabine may be a promising strategy in UBC. 
INTRODUCTION AND OBJECTIVES:
Gene therapy is rapidly evolving in the treatment of bladder cancer. We reported that intravesical adenoviral interferon-alpha (Ad-IFNa) produced a complete response in 35% of patients with BCG-unresponsive disease. Lentivirus (LV) is another potential vector for intravesical delivery of IFNa, which unlike adenovirus, can integrate into the host genome allowing for e712 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
